腎細胞癌の治療第3報:インターフェロン療法

概要

論文の詳細を見る
進行腎細胞癌患者の10例に対して8例にHuman lymphoblastoid interferon,他の2例にrecombinant Human leukocyte interferonを用いて治療を行ない,1)評価可能な9例に対して8週以後に効果判定を行なった結果,CR 1例,NC 3例,PD 5例であった.2)副作用は発熱,食欲不振,全身倦怠感が高頻度に出現した.そのために3例では治療を中止した.また,骨髄抑制として白血球減少,血小板減少もみられたが,そのため投与を中止した症例はなかった.3) IFHuman lymphoblastoid interferon (HLBI-alpha) or recombinant human leukocyte interferon (HLIF-alpha) was administered to ten patients suffering from renal cell carcinoma at a daily dose of 5 X 10(6) units. The efficacy of interferon was assessed in nine patients who had received HLBI-alpha or HLIF-alpha for more than eight weeks. One patient (11%) demonstrated complete response (CR), three patients (33%) showed no change and five patients (56%) continued to have progressive disease. CR was obtained after 30 weeks under HLBI-alpha and FT-207 combination therapy. The main side effects were fever, anorexia, general fatigue and hematologic toxicities. Cessation of interferon therapy due to side effects was necessary in three patients. In conclusion interferon is one of the most valuable agents in the treatment of renal cell carcinoma.